Skip to main content

Table 1 Demographic and clinical characteristics of patients with RA

From: Modulation of B cell activation by extracellular vesicles and potential alteration of this pathway in patients with rheumatoid arthritis

 

HD

RA

n

19

13

Agea

49 (35 − 53)

61 (53 − 63)

Female

17/19

12/13

DAS28a

n.a

2.20 (2.00 − 2.94)

CCP3 IgG U/mLa

n.a

395 (37 − 1042)

RF IgM U/mLa

n.a

21 (4 − 51)

Therapies

Methotrexate

n.a

3/13

Prednisolone

n.a

2/13

Leflunomide

n.a

3/13

Chloroquine

n.a

4/13

Deflazacort

n.a

2/13

Sulfasalazine

n.a

2/13

  1. aMedian (interquartile range). n.a. Not applicable